The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $54.82 which represents a decrease of $-2.64 or -4.59% from the prior close of $57.46. The stock opened at $57.08 and touched a ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Moderna (NasdaqGS:MRNA) with a Market Perform ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the ...

Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

The Vineyard boards of health are teaming up to bring vaccines back to the community at the end of the month. It’s not the ...

Factors associated with increased flare rates post-vaccination included active disease at the time, female sex, and -- most ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...